 |
0 Diseases |  |
29 Trials |
|
29 Trials |  |
1503 News |  |
| «12...12131415161718192021222324» |
- ||| loperamide / Generic mfg.
New trial: RCTFMTobesity: Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe Obesity (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=60, Not yet recruiting, Sponsor: University Hospital of North Norway
- | methoxyamine (TRC102) / Tracon Pharma
Phase classification, Combination therapy: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Jul 26, 2017
P1/2, N=65, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P1/2
- | loperamide / Generic mfg.
New trial, Surgery: Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=100, Recruiting, Sponsor: Mirna Abraham-Nordling
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jul 11, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Phase classification: P1 --> P1/2 Trial primary completion date: Dec 2018 --> Dec 2019
- |||| Verzenio (abemaciclib) / Eli Lilly
Trial completion, Enrollment change, Combination therapy, Monotherapy: neoMONARCH: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - May 18, 2017
P2, N=224, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed | N=148 --> 224
- | Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - May 4, 2017
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=148 --> 224 Trial primary completion date: Apr 2017 --> Apr 2018
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Apr 7, 2017
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: May 2017 --> Dec 2018
- | Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
New P2 trial, Monotherapy: Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib (clinicaltrials.gov) - Mar 29, 2017
P2, N=23, Recruiting, Sponsor: University of California, San Francisco
- loperamide / Generic mfg.
Trial primary completion date: Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies (clinicaltrials.gov) - Jan 31, 2017
P3, N=220, Recruiting, Sponsor: Cedars-Sinai Medical Center
Trial primary completion date: May 2017 --> Dec 2018 Trial primary completion date: Nov 2016 --> Dec 2017
- | pregabalin / Generic mfg.
New P4 trial: Pregabalin for Opiate Withdrawal Syndrome (clinicaltrials.gov) - Jan 11, 2017
P4, N=80, Recruiting, Sponsor: St. Petersburg Bekhterev Research Psychoneurological Institute
- ||| Nerlynx (neratinib) / Puma
Enrollment change, Trial primary completion date: CONTROL: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide (clinicaltrials.gov) - Jan 11, 2017
P2, N=240, Recruiting, Sponsor: Puma Biotechnology, Inc.
Trial primary completion date: Nov 2016 --> Dec 2017 N=120 --> 240 | Trial primary completion date: Oct 2016 --> Jan 2019
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Dec 12, 2016
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
N=120 --> 240 | Trial primary completion date: Oct 2016 --> Jan 2019 Trial primary completion date: Nov 2016 --> May 2017
- loperamide / Generic mfg., azithromycin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea (clinicaltrials.gov) - Nov 27, 2016
P=N/A, N=384, Terminated, Sponsor: Uniformed Services University of the Health Sciences
N=510 --> 384 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Mar 2016; AWD arm was completed. ADF diarrhea arm was unable to fill completely and there are no funds remaining to continue recruiting/enrolling.
- ||||| Viberzi (eluxadoline) / AbbVie
New P4 trial: Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use (clinicaltrials.gov) - Nov 8, 2016
P4, N=340, Recruiting, Sponsor: Allergan
- efavirenz / Generic mfg., ritonavir / Generic mfg.
Trial completion: dLOP: Efavirenz and Ritonavir on Human Brain P-Glycoprotein (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=13, Completed, Sponsor: Washington University School of Medicine
ADF diarrhea arm was unable to fill completely and there are no funds remaining to continue recruiting/enrolling. Active, not recruiting --> Completed
- loperamide / Generic mfg.
Enrollment change, Trial termination: Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study (clinicaltrials.gov) - Oct 11, 2016
P3, N=12, Terminated, Sponsor: Odense University Hospital
Active, not recruiting --> Completed N=42 --> 12 | Recruiting --> Terminated; Insuficcient recruiting
- vancomycin / Generic mfg., loperamide / Generic mfg.
Trial initiation date: Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection (clinicaltrials.gov) - Sep 27, 2016
P2/3, N=50, Not yet recruiting, Sponsor: Queen Elizabeth II Health Sciences Centre
N=42 --> 12 | Recruiting --> Terminated; Insuficcient recruiting Initiation date: Mar 2016 --> Dec 2016
- |||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Metastases: nextMONARCH 1: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (clinicaltrials.gov) - Sep 20, 2016
P2, N=225, Recruiting, Sponsor: Eli Lilly and Company
Initiation date: Mar 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Phase classification, Enrollment change: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Sep 14, 2016
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123
- methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date, Combination therapy: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Sep 7, 2016
P1, N=65, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123 Trial primary completion date: Jan 2017 --> Dec 2019
- loperamide / Generic mfg.
New trial, Combination therapy: Tibial Nerve Stimulation in Combination With Biofeedback (clinicaltrials.gov) - Sep 6, 2016
P=N/A, N=0, Recruiting, Sponsor: University Hospital, Linkoeping
- | loperamide / Generic mfg.
Trial completion: Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe) (clinicaltrials.gov) - Aug 15, 2016
P3, N=294, Completed, Sponsor: NICHD Pelvic Floor Disorders Network
Trial primary completion date: Jan 2017 --> Dec 2019 Active, not recruiting --> Completed
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion, Trial primary completion date: A Study of Abemaciclib in Healthy Participants (clinicaltrials.gov) - Aug 12, 2016
P1, N=40, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Enrollment change, Combination therapy, Monotherapy: neoMONARCH: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Jul 23, 2016
P2, N=148, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016 Recruiting --> Active, not recruiting | N=220 --> 148
- Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of Abemaciclib in Healthy Participants (clinicaltrials.gov) - Jun 16, 2016
P1, N=40, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=220 --> 148 Trial primary completion date: Jun 2016 --> Nov 2016
- loperamide / Generic mfg.
Trial suspension, Trial primary completion date: Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy (clinicaltrials.gov) - May 3, 2016
P4, N=120, Suspended, Sponsor: VA Medical Center, Houston
Trial primary completion date: Jun 2016 --> Nov 2016 Recruiting --> Suspended | Trial primary completion date: Dec 2009 --> Dec 2013
- Impracor (ketoprofen) / Harrow Health
Trial completion, Enrollment change, Trial primary completion date: Novel Topical Therapies for the Treatment of Genital Pain (clinicaltrials.gov) - Apr 27, 2016
P2/3, N=9, Completed, Sponsor: University of Rochester
Recruiting --> Suspended | Trial primary completion date: Dec 2009 --> Dec 2013 Enrolling by invitation --> Completed | N=30 --> 9 | Trial primary completion date: Dec 2015 --> Jun 2015
- ||||| Verzenio (abemaciclib) / Eli Lilly
New P2 trial, Metastases: nextMONARCH 1: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (clinicaltrials.gov) - Apr 21, 2016
P2, N=225, Not yet recruiting, Sponsor: Eli Lilly and Company
- loperamide / Generic mfg.
New trial: Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing (clinicaltrials.gov) - Mar 18, 2016
P0, N=34, Completed, Sponsor: Rush University Medical Center
- Verzenio (abemaciclib) / Eli Lilly
Enrollment open: A Study of Abemaciclib in Healthy Participants (clinicaltrials.gov) - Mar 9, 2016
P1, N=40, Recruiting, Sponsor: Eli Lilly and Company
Enrolling by invitation --> Completed | N=30 --> 9 | Trial primary completion date: Dec 2015 --> Jun 2015 Not yet recruiting --> Recruiting
- Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Mar 5, 2016
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- vancomycin / Generic mfg., loperamide / Generic mfg.
New P2/3 trial: Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection (clinicaltrials.gov) - Feb 21, 2016
P2/3, N=50, Not yet recruiting, Sponsor: Queen Elizabeth II Health Sciences Centre
- loperamide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Educational-Medical-Behavioral Treatment of Fecal Incontinence (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=31, Terminated, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Apr 2016 --> Apr 2017 N=252 --> 31 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2015; Low enrollment led sponsor to terminate study early.
- | Verzenio (abemaciclib) / Eli Lilly
New P1 trial: A Study of Abemaciclib in Healthy Participants (clinicaltrials.gov) - Feb 9, 2016
P1, N=40, Not yet recruiting, Sponsor: Eli Lilly and Company
- methoxyamine (TRC102) / Tracon Pharma
Trial primary completion date, Combination therapy: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Feb 8, 2016
P1, N=55, Recruiting, Sponsor: National Cancer Institute (NCI)
N=252 --> 31 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2016 --> Mar 2015; Low enrollment led sponsor to terminate study early. Trial primary completion date: Jan 2016 --> Jan 2017
- ||| Nerlynx (neratinib) / Puma
Enrollment change: CONTROL: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide (clinicaltrials.gov) - Jan 28, 2016
P2, N=120, Recruiting, Sponsor: Puma Biotechnology, Inc.
Trial primary completion date: Jan 2016 --> Jan 2017 N=70 --> 120
- loperamide / Generic mfg.
Trial primary completion date: Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies (clinicaltrials.gov) - Jan 27, 2016
P3, N=220, Recruiting, Sponsor: Cedars-Sinai Medical Center
N=70 --> 120 Trial primary completion date: Nov 2015 --> Nov 2016
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment closed: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Jan 26, 2016
P1, N=102, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Nov 2015 --> Nov 2016 Recruiting --> Active, not recruiting
- efavirenz / Generic mfg., ritonavir / Generic mfg.
Trial primary completion date: dLOP: Efavirenz and Ritonavir on Human Brain P-Glycoprotein (clinicaltrials.gov) - Jan 17, 2016
P=N/A, N=8, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Jun 2016
- aspirin / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date: ASPIDIA: Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies. (clinicaltrials.gov) - Dec 9, 2015
P2, N=0, Withdrawn, Sponsor: Centre Francois Baclesse
Trial primary completion date: Jun 2014 --> Jun 2016 N=70 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2017 --> Dec 2015
- | loperamide / Generic mfg.
Enrollment open: ILEHOS: Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study (clinicaltrials.gov) - Oct 23, 2015
P3, N=90, Recruiting, Sponsor: University Hospital, Strasbourg, France
N=70 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2017 --> Dec 2015 Active, not recruiting --> Recruiting
- amiodarone / Generic mfg.
Enrollment change, Trial withdrawal: Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) (clinicaltrials.gov) - Oct 6, 2015
P2/3, N=0, Withdrawn, Sponsor: Emergency NGO Onlus
Active, not recruiting --> Recruiting N=132 --> 0 | Not yet recruiting --> Withdrawn
- | loperamide / Generic mfg.
Enrollment closed: Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe) (clinicaltrials.gov) - Oct 6, 2015
P3, N=294, Active, not recruiting, Sponsor: NICHD Pelvic Floor Disorders Network
N=132 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- methoxyamine (TRC102) / Tracon Pharma
Enrollment change, Combination therapy: TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (clinicaltrials.gov) - Oct 1, 2015
P1, N=55, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=40 --> 55
- | loperamide / Generic mfg.
Enrollment closed: ILEHOS: Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study (clinicaltrials.gov) - Sep 22, 2015
P3, N=90, Active, not recruiting, Sponsor: University Hospital, Strasbourg, France
N=40 --> 55 Not yet recruiting --> Active, not recruiting
- |||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Combination therapy, Monotherapy: neoMONARCH: A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Sep 17, 2015
P2, N=220, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion, Metastases: ADAM-Afatinib Diarrhea Assessment and Management (clinicaltrials.gov) - Aug 11, 2015
P3, N=40, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | loperamide / Generic mfg.
Enrollment open: Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies (clinicaltrials.gov) - Aug 11, 2015
P3, N=220, Recruiting, Sponsor: Cedars-Sinai Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | loperamide / Generic mfg.
New P2 trial: Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research (clinicaltrials.gov) - Aug 7, 2015
P2, N=342, Not yet recruiting, Sponsor: Shanghai Yueyang Integrated Medicine Hospital
- loperamide / Generic mfg.
Trial primary completion date: ILEHOS: Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study (clinicaltrials.gov) - Jun 30, 2015
P3, N=90, Not yet recruiting, Sponsor: University Hospital, Strasbourg, France
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2019 --> Oct 2019